Gastroenterology Research and Practice

Epigenetic Aberrance and Its Clinical Relevance in Gastrointestinal Cancer

Publishing date
11 Apr 2014
Submission deadline
22 Nov 2013

Lead Editor
Guest Editors

1Department of Medicine, University of Saskatchewan College of Medicine, 103 Hospital Drive, Saskatoon, SK, Canada S7J3J2

2Department of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, 528 Zhangheng Road, Shanghai 201203, China

3Department of Surgery B at Meir Medical Center, Tel Aviv, Israel

This issue is now closed for submissions.
More articles will be published in the near future.

Epigenetic Aberrance and Its Clinical Relevance in Gastrointestinal Cancer

This issue is now closed for submissions.
More articles will be published in the near future.


In recent years, epigenetic aberrations have been increasingly recognized as important alternative mechanisms of carcinogenesis and tumor progress in many kinds of human cancers, which lead to loss or downregulation of tumor suppressor genes and upregulation of some tumor promoting genes or oncogenes. The modern definition of epigenetics is information heritable during cell division other than the DNA sequence itself, which affects changes in gene expression during development and includes phenomena such as DNA methylation, histone modification, loss of genomic imprinting, and RNA associated silencing. DNA methylation is a covalent modification of cytosine occurring on so-called CpG islands, which are short CpG-rich regions frequently associated with gene promoter regions. Normally, cytosine methylation of CpG sites within the gene promoter region is involved in the allele-specific inactivation of certain genes, while CpG methylation in the chromosomal centromeric region contributes to chromosomal stability. Histone modification includes posttranscriptional acetylation, methylation, or phosphorylation of histone tails.

We have a particular interest in manuscripts that report relevance of epigenetic aberrance for population screening, early diagnosis, molecular staging, epigenetic therapeutic targets, and treatment outcome or prognosis prediction in gastrointestinal cancer. Reviews that summarize the results of basic, clinical, and in particular translational studies are welcomed. Moreover, manuscripts reporting studies using current high throughput techniques and bioinformatic analysis would be of great interest. Potential topics include, but are not limited to:

  • New methods of epigenetic aberrance detection
  • Epigenetic aberrances and cancer stem cells
  • Epigenetics and signal transduction
  • Epigenetic biomarkers or predictors for population screening, early diagnosis, molecular staging, and prognosis
  • Impact of epigenetic aberrance on clinical management of patients with gastrointestinal cancer
  • Targeted epigenetic therapy

Before submission authors should carefully read over the journal’s Author Guidelines which are located at Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at according to the following timetable:

Gastroenterology Research and Practice
 Journal metrics
Acceptance rate29%
Submission to final decision68 days
Acceptance to publication32 days
Impact Factor1.825

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.